Gilead Sciences to launch authorized generics of two hepatitis C drugs
The authorized generics, announced amid HCV product pricing pressures, will cost $24,000 - less than one-third the branded drugs' prices - to reflect discounts given to payers.
The authorized generics, announced amid HCV product pricing pressures, will cost $24,000 - less than one-third the branded drugs' prices - to reflect discounts given to payers.
Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk// // In January 2015, Advera Health released a Drug Safety Monitor analysis comparing the safety of then newly approved Hepatitis C drugs Viekira Pak to Harvoni and Solvaldi (hereafter just Harvoni). Our analysts concluded, …both Harvoni and Sovaldi appear […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Last week’s blog post discussed the dangerous precedent that exclusivity deals between drug manufacturers and payers set. Deals like the one Express Scripts and AbbVie’s signed for discounted rates on the new Hepatitis C drug, Viekira Pak. I argued that these deals emphasize the payer trend of focusing on immediate savings rather than overall outcomes, […]